Condition: Metastatic Oesogastric Adenocarcinoma · Sponsor: Federation Francophone de Cancerologie Digestive
Advanced cancer of the stomach and the gastro-esophageal junction (G/GEJ) remains a very serious disease. Today, only about 10-15% of patients are alive after 5 years. Treatments mainly aim to control symptoms, extend life, and maintain quality of life. First treatments usually combine two chemotherapies, but recent years have brought real progress. Immunotherapy - drugs that "unlock" the immune system - has shown clear benefits. For patients whose tumors have certain markers (like PD-L1), combining drugs such as nivolumab or pembrolizumab with chemotherapy can help patients live longer. Another breakthrough is zolbetuximab, a targeted therapy that attacks a protein (Claudin 18.2) found on many gastric cancers, also improving survival. When cancer grows despite these therapies, second-line treatments are used. The most common is chemotherapy with paclitaxel + ramucirumab, which blocks the tumor's blood supply. These drugs extend survival, but usually only by a few months. For patients who need a third option, the oral drug trifluridine/tipiracil (TAS-102) can provide extra time, though benefits remain limited. That's why researchers are now exploring combinations. Since stomach tumors rely on forming new blood vessels, combining trifluridine/tipiracil with anti-angiogenic drugs - medicines that cut off the tumor's blood supply - looks promising. One of the most exciting of these drugs is fruquintinib, already proven effective in colorectal cancer. A new international tria…
This description comes directly from the study's public registry record.
Project manager · +33(0)3 80 66 80 13 · prodige114.fruquitas@ffcd.fr
Always discuss trial participation with your own doctor first.
| Centre Hospitalier | Aurillac, France | Not Yet Recruiting |
| Institut Sainte Catherine | Avignon, France | Not Yet Recruiting |
| Centre Hospitalier | Bayeux, France | Not Yet Recruiting |
| Bayonne- Clinique Belharra | Bayonne, France | Not Yet Recruiting |
| Centre Hospitalier Côte Basque | Bayonne, France | Not Yet Recruiting |
| ICONE | Bezannes, France | Not Yet Recruiting |
| BORDEAUX-Institut Bergonié | Bordeaux, France | Not Yet Recruiting |
| Clinique Tivoli | Bordeaux, France | Not Yet Recruiting |
| C.H.U. de Brest | Brest, France | Not Yet Recruiting |
| Cac - François Baclesse | Caen, France | Not Yet Recruiting |
| CHU Côte de Nacre | Caen, France | Not Yet Recruiting |
| Ch - Jean Rougier | Cahors, France | Not Yet Recruiting |
+ 52 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07270991